AstraZeneca’s Enhertu Approved for Expanded Breast Cancer Use in India
By ThePip Desk
AstraZeneca’s Enhertu receives CDSCO approval for expanded HER2-positive breast cancer treatment in India, offering new hope for patients with residual disease.
AstraZeneca Pharma India has secured crucial permission from the Central Drugs Standard Control Organization (CDSCO) for an additional indication of its drug, Enhertu. This approval specifically allows for the import, sale, and distribution of Trastuzumab Deruxtecan 100mg/5mL lyophilized powder.
Expanding Enhertu’s Reach
This new regulatory nod positions Enhertu, also known as Trastuzumab Deruxtecan, for adjuvant treatment in a specific patient demographic. It targets adult patients with HER2-positive breast cancer, particularly those demonstrating residual invasive disease following prior therapies.
The expanded indication specifies its use for patients who meet several key criteria:
- They must have HER2-positive (IHC 3+ or ISH+) breast cancer.
- Patients must exhibit residual invasive disease after neoadjuvant treatment.
- This prior treatment includes Trastuzumab (with or without Pertuzumab) and taxane-based regimens.
Strategic Market Expansion
The CDSCO’s permission marks a significant step, directly paving the way for Enhertu’s marketing in India for this specified additional indication. Its full market entry, however, remains contingent upon the receipt of any further related statutory approvals.
For AstraZeneca Pharma India, this development aligns with its broader strategic focus as a global biopharmaceutical company. The firm is dedicated to the discovery, development, and commercialization of innovative medicines across several core healthcare areas.
AstraZeneca operates distinctively across its Healthcare and Clinical Trial segments within India. Its primary areas of research and development encompass cardiovascular/metabolic disease, cancer treatment, and respiratory, inflammatory, and autoimmune conditions.